<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have studied somatic cell hybrids between mouse <z:mp ids='MP_0009440'>myeloma</z:mp> cells and IARC-BL2 Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> human cells carrying a t(8;22) chromosome translocation for the presence and expression of human immunoglobin lambda chains and for the c-myc oncogene </plain></SENT>
<SENT sid="1" pm="."><plain>The results indicate that the c-myc oncogene remains on the 8q+ chromosome and that the excluded and rearranged C lambda allele translocates from chromosome 22 to this chromosome 8 </plain></SENT>
<SENT sid="2" pm="."><plain>As a result of the translocation, transcriptional activation of the c-myc oncogene on the rearranged chromosome 8 (8q+) occurs, while the c-myc oncogene in the <z:mpath ids='MPATH_458'>normal</z:mpath> chromosome 8 is transcriptionally silent </plain></SENT>
<SENT sid="3" pm="."><plain>These findings suggest that the translocation of a rearranged immunoglobulin locus to the 3' side of an unrearranged c-myc oncogene may enhance its transcription and contribute to <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
</text></document>